Clinical Trial Update: A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TIN816 in patients at risk for acute kidney injury following cardiac surgery was terminated; results were posted on 2026-04-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• TIN816

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Kidney Injury Following Cardiac Surgery | Phase 2 | Status: TERMINATED | Results posted: 2026-04-02